Cargando…
Stellate Ganglion Block Reduces Anxiety Symptoms by Half: A Case Series of 285 Patients
The stellate ganglion block (SGB) procedure has been used successfully for over twelve years to treat thousands of patients suffering from posttraumatic stress disorder (PTSD). Level 1b evidence supports this use of SGB, but no studies to date have reported specifically on anxiety symptom improvemen...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303073/ https://www.ncbi.nlm.nih.gov/pubmed/37373947 http://dx.doi.org/10.3390/jpm13060958 |
_version_ | 1785065192395112448 |
---|---|
author | Lynch, James H. Mulvaney, Sean W. Bryan, Craig J. Hernandez, David |
author_facet | Lynch, James H. Mulvaney, Sean W. Bryan, Craig J. Hernandez, David |
author_sort | Lynch, James H. |
collection | PubMed |
description | The stellate ganglion block (SGB) procedure has been used successfully for over twelve years to treat thousands of patients suffering from posttraumatic stress disorder (PTSD). Level 1b evidence supports this use of SGB, but no studies to date have reported specifically on anxiety symptom improvements following SGB. We collected Generalized Anxiety Disorder questionnaire (GAD-7) scores pre-procedure and at 1-week and 1-month post-procedure from 285 patients. The mean baseline GAD-7 score of 15.9 (indicating severe anxiety) declined significantly following SGB treatment. Changes in GAD-7 scores ≥ 4 were considered clinically meaningful. From baseline to 1 week, the GAD-7 scores dropped by 9.0 points (95% CI = 8.3–9.7, p < 0.001, d = 1.8), with 211 (79.6%) patients demonstrating clinically meaningful improvement. Furthermore, from baseline to 1 month, the GAD-7 scores dropped by 8.3 points (95% CI = 7.6–9.0, p < 0.001, d = 1.7), with 200 (75.5%) patients demonstrating clinically meaningful improvement. The stellate ganglion block treatment resulted in a decrease of GAD-7 scores of over twice the minimal clinically important difference in treating anxiety for at least 1 month following SGB. Given the results from this retrospective observational study, larger prospective studies should be conducted to determine the effects of SGB treatment as a novel therapeutic treatment for generalized anxiety disorder and other anxiety disorders. |
format | Online Article Text |
id | pubmed-10303073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103030732023-06-29 Stellate Ganglion Block Reduces Anxiety Symptoms by Half: A Case Series of 285 Patients Lynch, James H. Mulvaney, Sean W. Bryan, Craig J. Hernandez, David J Pers Med Brief Report The stellate ganglion block (SGB) procedure has been used successfully for over twelve years to treat thousands of patients suffering from posttraumatic stress disorder (PTSD). Level 1b evidence supports this use of SGB, but no studies to date have reported specifically on anxiety symptom improvements following SGB. We collected Generalized Anxiety Disorder questionnaire (GAD-7) scores pre-procedure and at 1-week and 1-month post-procedure from 285 patients. The mean baseline GAD-7 score of 15.9 (indicating severe anxiety) declined significantly following SGB treatment. Changes in GAD-7 scores ≥ 4 were considered clinically meaningful. From baseline to 1 week, the GAD-7 scores dropped by 9.0 points (95% CI = 8.3–9.7, p < 0.001, d = 1.8), with 211 (79.6%) patients demonstrating clinically meaningful improvement. Furthermore, from baseline to 1 month, the GAD-7 scores dropped by 8.3 points (95% CI = 7.6–9.0, p < 0.001, d = 1.7), with 200 (75.5%) patients demonstrating clinically meaningful improvement. The stellate ganglion block treatment resulted in a decrease of GAD-7 scores of over twice the minimal clinically important difference in treating anxiety for at least 1 month following SGB. Given the results from this retrospective observational study, larger prospective studies should be conducted to determine the effects of SGB treatment as a novel therapeutic treatment for generalized anxiety disorder and other anxiety disorders. MDPI 2023-06-06 /pmc/articles/PMC10303073/ /pubmed/37373947 http://dx.doi.org/10.3390/jpm13060958 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Lynch, James H. Mulvaney, Sean W. Bryan, Craig J. Hernandez, David Stellate Ganglion Block Reduces Anxiety Symptoms by Half: A Case Series of 285 Patients |
title | Stellate Ganglion Block Reduces Anxiety Symptoms by Half: A Case Series of 285 Patients |
title_full | Stellate Ganglion Block Reduces Anxiety Symptoms by Half: A Case Series of 285 Patients |
title_fullStr | Stellate Ganglion Block Reduces Anxiety Symptoms by Half: A Case Series of 285 Patients |
title_full_unstemmed | Stellate Ganglion Block Reduces Anxiety Symptoms by Half: A Case Series of 285 Patients |
title_short | Stellate Ganglion Block Reduces Anxiety Symptoms by Half: A Case Series of 285 Patients |
title_sort | stellate ganglion block reduces anxiety symptoms by half: a case series of 285 patients |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303073/ https://www.ncbi.nlm.nih.gov/pubmed/37373947 http://dx.doi.org/10.3390/jpm13060958 |
work_keys_str_mv | AT lynchjamesh stellateganglionblockreducesanxietysymptomsbyhalfacaseseriesof285patients AT mulvaneyseanw stellateganglionblockreducesanxietysymptomsbyhalfacaseseriesof285patients AT bryancraigj stellateganglionblockreducesanxietysymptomsbyhalfacaseseriesof285patients AT hernandezdavid stellateganglionblockreducesanxietysymptomsbyhalfacaseseriesof285patients |